Cellyan Biotechnology Co. vs 111
111 is the larger business, with $1.75bn of revenue in fiscal 2025 against $13.4m for Cellyan Biotechnology Co. (130.1 times as much). 111 grew faster (-12.7% against -33.9%). 111 kept more of each dollar of sales as profit: a net margin of -0.5% against -8.5%.
| Latest fiscal year | Cellyan Biotechnology Co.HKPD, 2026 | 111YI, 2025 |
|---|---|---|
| Revenue | $13.4m | $1.75bn |
| Revenue growth | -33.9% | -12.7% |
| Net income | −$1.1m | −$9.2m |
| Operating margin | -17.8% | -0.0% |
| Net margin | -8.5% | -0.5% |
| Return on equity | -15.5% | — |
| Free cash flow | −$787,072 | $16.0m |
| Cash | $221,841 | $73.1m |
| Total debt | $877,904 | $26.8m |
| Debt to equity | 9.1% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $30.1m | $26.3m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 36 sales |